整合强化学习和蒙特卡洛树寻找增强的新抗原疫苗设计
Yicheng Lin1,2, Jiakang Ma1,2, Haozhe Yuan1,2
1MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences and Shanghai Xuhui Central Hospital, Fudan University, 131 DongAn Road, Shanghai, 200032, China.
一个新的算法UltraMutate通过发现与人类白细胞抗原 (HLA) 分子结合更强的突变来增强新抗原疫苗设计. 这种方法提高了癌症免疫治疗中强大的适应性免疫反应的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 计算生物学 计算生物学
- 生物信息学是一种生物信息学.
背景情况:
- 癌症免疫疗法在新抗原疫苗方面表现有前途.
- 薄弱的-HLA结合亲和力可以限制疫苗的疗效和适应性免疫反应.
- 通过突变增强-HLA结合是改善疫苗设计的潜在策略.
研究的目的:
- 介绍UltraMutate,一种用于识别具有增强与人白细胞抗原 (HLA) 分子结合亲和力的突变的新算法.
- 确保识别的突变与原始新抗原保持高同质性,保持潜在的免疫性.
- 改进针对个性化免疫治疗的基于新抗原的疫苗的设计.
主要方法:
- 开发了UltraMutate,这是一个整合强化学习和蒙特卡罗树搜索的算法.
- 利用酸-HLA结合亲和力和同质性指标用于突变识别.
- 在3660个-HLA对的独立测试集上验证了UltraMutate的性能.
主要成果:
- 超突变鉴定出具有显著增强的结合亲和力以准HLA分子的类突变.
- 该算法成功地保留了突变和原始新抗原之间的高同质性.
- 在识别增强亲和力的突变方面,UltraMutate的表现优于现有的最先进的方法.
- 在设计针对人类乳头瘤病毒和人类细胞巨化病毒的类疫苗中证明了适用性.
结论:
- 超变种是设计有效的基于新抗原的疫苗的强大工具.
- 该算法解决了免疫治疗中弱-HLA结合的挑战.
- 超变种具有推动个性化癌症免疫疗法的巨大潜力.
更多相关视频
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Vaccinations
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
